F. Hoffmann-La Roche Ltd (Switzerland)

MannKind Corporation (U.S.)

OMRON Healthcare, Inc. (Japan)

Mylan N.V (U.S.)

3M (U.S.)

Koninklijke Philips N.V. (Netherlands)

Merck & Co., Inc., (U.S.)

Teva Pharmaceutical Industries Ltd. (Israel)

Sunovion Pharmaceuticals Inc. (U.S.)

PARI GmbH (Germany)

Jabil Inc. (U.S.)

AstraZeneca (U.K.)

Boehringer Ingelheim International GmbH. (Germany)

GSK plc. (U.K.)

Novartis AG (Switzerland)

Aerogen Pharma (Ireland)

Briggs Healthcare (U.S.)

HAAG-STREIT GROUP (Switzerland)

Janssen Global Services, LLC (U.S.)

AptarGroup, Inc. (U.S.)

The pulmonary drug delivery market is analysed and market size insights and trends are provided by country, formulations, canister type, application, and end-user as referenced above.

The countries covered in the pulmonary drug delivery market  report are  U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the growing prevalence of respiratory and lung disorders, technological advancement, and increasing awareness. Furthermore, through an increase in the prevalence of pulmonary diseases, the presence of major players in the production and development of drugs for pulmonary diseases, an increase in the number of hospitals and diagnostic facilities, and government initiatives for treating pulmonary diseases in the area.

Asia-Pacific is expected to show a rapid and lucrative growth rate in the forecast period owing to Japan's increasing disposable and rising geriatric population. Moreover, the rising patient count with respiratory and acceptance of pulmonary drug devices will boost the region market, whereas increasing government initiatives to improve healthcare infrastructure will also expand market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.